Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28491550 | 1.00 | HTR2C (0.49) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| SCHEMBL20063859 | 1.00 | HTR2C (0.49) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL28517839 | 0.99 | HTR2C (0.50) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL21294710 | 0.99 | HTR2C (0.50) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| SCHEMBL29481989 | 0.91 | HTR2C (0.46) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| SCHEMBL21294717 | 0.91 | HTR2C (0.46) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| SCHEMBL31495941 | 0.90 | HTR2C (0.49) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| SCHEMBL21294957 | 0.89 | SCN9A (0.46) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| SCHEMBL29481970 | 0.89 | SCN9A (0.46) | HTR2CDRD2SCN9AHTR2AHTR2B | |
| SCHEMBL21306749 | 0.86 | SCN9A (0.40) | SCN9AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3797101-A1 | PYRIDIDNE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2019165290-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | GENENTECH, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | HTR2C 2475/4885DRD2 3912/4885SCN9A 2136/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | HTR2C 823/4885DRD2 2128/4885SCN9A 90/4885 |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | HTR2C 1243/4885DRD2 1844/4885SCN9A 1478/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | HTR2C 1243/4885DRD2 1844/4885SCN9A 1478/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | HTR2C 823/4885DRD2 2128/4885SCN9A 90/4885 |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | SCN1B, CACNA1A, SCN1A | HTR2C 1626/4885DRD2 1829/4885SCN9A 36/4885 |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, CACNA1A, SCN1A | HTR2C 1563/4885DRD2 1985/4885SCN9A 34/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | HTR2C 1184/4885DRD2 1936/4885SCN9A 1501/4885 |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | F12, REN, ZYX | HTR2C 2002/4885DRD2 997/4885SCN9A 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.